Table 1 All-night Sleep Variables

From: Different Effects of Phenelzine Treatment on EEG Topography in Waking and Sleep in Depressed Patients

Variable BL P5 F1,7 (p <)
Time in bed (min) 452.5 (15.8) 462.1 (20.3) 0.2 (0.71)
Sleep episode (min) 433.0 (17.4) 445.3 (18.5) 0.3 (0.63)
Total sleep time (min) 384.7 (18.5) 373.2 (22.5) 1.0 (0.36)
Sleep efficiency (%) 85.3 (3.6) 80.6 (2.6) 1.0 (0.37)
Sleep latency (min) 14.7 (2.8) 15.9 (3.1) 0.1 (0.76)
REM latency (min) 68.6 (5.1) 303.3 (41.4) 33.2 (0.02)
WASO (min) 47.6 (17.3) 68.0 (13.8) 7.1 (0.02)
Movement time (min) 5.5 (0.8) 5.1 (1.3) 0.2 (0.68)
Stage 1 (min) 44.3 (3.0) 33.6 (8.9) 2.2 (0.19)
Stage 2 (min) 225.0 (9.9) 275.0 (19.8) 12.3 (0.01)
Stage 3 (min) 21.9 (5.3) 35.0 (9.5) 2.6 (0.16)
Stage 4 (min) 27.8 (9.0) 26.0 (8.7) 0.0 (0.86)
Slow wave sleep (min) 49.8 (13.1) 61.5 (17.8) 0.9 (0.39)
REM sleep (min) 65.7 (7.4) 3.0 (1.4) 96.8 (0.01)
  1. Values represent means (SEM) of 8 subjects. BL: pre-treatment baseline. P5: week 5–6 of phenelzine treatment. Time in bed: time between lights-out and lights-on. Sleep episode: time between sleep onset and final awakening. Sleep efficiency: total sleep time per time in bed. Sleep latency: time from lights-off to the first occurrence of Stage 2. REM latency: time from sleep onset to the first occurrence of REM sleep. REM sleep: rapid-eye-movement sleep. WASO: wakefulness after sleep onset (stage 2). Stage 1, 2, 3 and 4: non-REM sleep stages. Slow wave sleep: stages 3 + 4.
  2. F and p values: One-way rANOVA with the within-factor Treatment (BL, P5).